Health care stocks were flat to slightly lower premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was down 0.01% and the iShares Biotechnology ETF (IBB) was flat recently.
Prime Medicine (PRME) shares rose nearly 19% after the company announced a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments